DSMB recommends continuation of Phase II for SB 9200 in HBV

Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) said an independent DSMB recommended continuation of the Phase II ACHIEVE trial evaluating SB 9200 in treatment-naïve HBV patients without cirrhosis. The company has begun enrollment in the second cohort of the trial.

The Phase IIa portion of the double-blind, placebo-controlled, international trial is evaluating once-daily 25, 50, 100 and 200 mg SB 9200 for 12 weeks followed by Viread tenofovir disoproxil fumarate monotherapy for 12 weeks in 80 patients. The Phase IIb portion is evaluating the combination in about 200 additional patients. The primary endpoint is safety. Secondary endpoints include pharmacokinetics, and change from baseline in hepatitis B e antigen (HBeAg) and HBV DNA levels at 6, 12 and 24 weeks...